Quebec预测模型:优化影像学正常纵隔的非小细胞肺癌侵入性纵隔分期
QPM纳入最大纵隔淋巴结大小、肿瘤中心性、cN1病变及病灶SUV,以预测概率>10%为阈值,开发集敏感度73.9%、特异度81.1%,验证集表现相似,且AUC 0.85优于现行指南标准。
要点
- QPM用于影像学正常纵隔的cTxN0/N1M0非小细胞肺癌,预测隐匿性纵隔病变概率。
- 以预测概率>10%为阈值,开发集敏感度73.9%、特异度81.1%、阴性预测值96.8%。
- QPM的AUC 0.85优于ACCP指南标准(0.65)和ESTS指南标准(0.60)。
核心结论
- QPM可整合CT和PET影像信息,帮助临床医生减少不会改变管理的侵入性分期操作,同时降低手术中发现意外纵隔病变的风险。
研究设计与样本
- 研究纳入2014至2018年在该机构经CT和PET-CT分期的cTxN0/N1M0非小细胞肺癌肿瘤患者,均接受金标准手术淋巴结清扫或术前侵入性纵隔分期证实隐匿性纵隔病变,分为开发集(n=502)和独立验证集(n=301)构建Quebec预测模型。
主要发现
- 预测模型包含最大纵隔淋巴结大小(P < .001)、肿瘤中心性(P = .23)、cN1病变存在(P = .29)和病灶标准化摄取值(P = .09)。
- 以计算概率>10%为阈值,开发集敏感度73.9%(95% CI,58.9%-85.7%)、特异度81.1%(95% CI,77.2%-84.6%)、阳性预测值28.3%(95% CI,23.4%-33.8%)、阴性预测值96.8%(95% CI,95.0%-98.1%)。
- 验证集表现相似(Hosmer-Lemeshow检验P = .77;Pearson χ2和未加权平方和统计量P = .5163;Stukel评分检验P = .0750)。
- QPM识别隐匿性纵隔病变的AUC为0.85(95% CI,0.80-0.90),优于ACCP指南标准(AUC 0.65,95% CI,0.59-0.71)和ESTS指南标准(AUC 0.60,95% CI,0.54-0.67)。
关键数值与推荐
- QPM以预测概率>10%作为识别隐匿性纵隔病变的阈值。
- 开发集敏感度73.9%(95% CI,58.9%-85.7%),特异度81.1%(95% CI,77.2%-84.6%),阳性预测值28.3%(95% CI,23.4%-33.8%),阴性预测值96.8%(95% CI,95.0%-98.1%)。
- QPM的AUC为0.85(95% CI,0.80-0.90),ACCP指南标准AUC为0.65(95% CI,0.59-0.71),ESTS指南标准AUC为0.60(95% CI,0.54-0.67)。
临床怎么用
- 对于影像学正常纵隔的cTxN0/N1M0非小细胞肺癌患者,可使用QPM计算隐匿性纵隔病变概率,以>10%为阈值辅助决定是否行侵入性纵隔分期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guideline-recommended criteria for invasive mediastinal staging in patients with a radiologically normal mediastinum fail to identify a significant proportion of patients with occult mediastinal disease (OMD), despite it leading to a large number of invasive staging procedures. RESEARCH QUESTION: Which variables available before surgery predict the probability of OMD in patients with a radiologically normal mediastinum? STUDY DESIGN AND METHODS: We identified all cTxN0/N1M0 non-small cell lung cancer tumors staged by CT imaging and PET with CT imaging in our institution between 2014 and 2018 who underwent gold standard surgical lymph node dissection or were demonstrated to have OMD before surgery by invasive mediastinal staging techniques and divided them into a derivation and an independent validation cohort to create the Quebec Prediction Model (QPM), which allows calculation of the probability of OMD. RESULTS: Eight hundred three patients were identified (development set, n = 502; validation set, n = 301) with a prevalence of OMD of 9.1%. The developed prediction model included largest mediastinal lymph node size (P < .001), tumor centrality (P = .23), presence of cN1 disease (P = .29), and lesion standardized uptake value (P = .09). Using a calculated probability of more than 10% as a threshold to identify OMD, this model had a sensitivity, specificity, positive predictive value, and negative predictive value in the derivation cohort of 73.9% (95% CI, 58.9%-85.7%), 81.1% (95% CI, 77.2%-84.6%), 28.3% (95% CI, 23.4%-33.8%), and 96.8% (95% CI, 95.0%-98.1%), respectively. It performed similarly in the validation cohort (P = .77, Hosmer-Lemeshow test; P = .5163, Pearson χ2 and unweighted sum-of-squares statistics; and P = .0750, Stukel score test) and outperformed current guideline-recommended criteria in identifying patients with OMD (area under the receiver operating characteristic curve [AUC] for American College of Chest Physicians guidelines criteria, 0.65 [95% CI, 0.59-0.71]; AUC for European Society of Thoracic Surgeons guidelines criteria, 0.60 [95% CI, 0.54-0.67]; and AUC for the QPM, 0.85 [95% CI, 0.80-0.90]). INTERPRETATION: The QPM allows the clinician to integrate available information from CT and PET imaging to minimize invasive staging procedures that will not modify management, while also minimizing the risk of unforeseen mediastinal disease found at surgery.
引用
- Guinde J, Bourdages-Pageau E, Collin-Castonguay MM, et al. A Prediction Model to Optimize Invasive Mediastinal Staging Procedures for Non-small Cell Lung Cancer in Patients With a Radiologically Normal Mediastinum: The Quebec Prediction Model. Chest. 2021. PMID: 34119514. doi:10.1016/j.chest.2021.05.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。